Trial Profile
A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2019
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Renal failure; Short stature; Somatotropin deficiency; Turner's syndrome
- Focus Therapeutic Use
- Sponsors LG Life Sciences
- 01 Jan 2019 Status changed from recruiting to completed.
- 13 Jan 2017 New trial record